Who is sponsoring NCT05933668?

NCT05933668 is sponsored by Peking University.

What condition does NCT05933668 study?

NCT05933668 studies Advanced Solid Tumor.

What is the status of NCT05933668?

NCT05933668 is currently NOT_YET_RECRUITING.

Last reviewed 2023-06-27 · How we verify

Phase I Clinical Study of YK0901 Injection for the Treatment of Advanced Solid Tumors With HLA-A * 11:01 Positive and KRAS G12V Mutation

NCT05933668 Phase 1 NOT_YET_RECRUITING

This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A \* 11:01).

Details

Lead sponsor	Peking University
Phase	Phase 1
Status	NOT_YET_RECRUITING
Enrolment	11
Start date	2023-07
Completion	2026-07

Conditions

Advanced Solid Tumor

Interventions

YK0901 cells

Primary outcomes

Dose-limiting toxicity (DLT) — 2 years
Treatment related AEs — 2 years

Countries

China